Is "longevity" the same as a longer life?

Not quite. In research, the focus is less on lifespan alone than on healthspan - that is, the years one spends without serious chronic disease and functional limitation. The goal is to age in good health, not to postpone dying endlessly.

Can peptides stop aging?

There is currently no robust proof of this in humans. Some peptides are being studied in basic research because they might act on mechanisms of aging, but most of the data come from cell and animal experiments. Statements that a peptide "stops aging" must be classified as an unsupported claim.

Are these compounds approved and safe?

The status varies greatly. Some of the substances studied are purely investigational or research substances, others are at best prescribed for narrowly defined medical indications - but not approved for "life extension". Purity, quality, and long-term safety are often unclear outside of medical supervision. For concrete considerations, medical advice is warranted.

Longevity Basics7 min readLast reviewed: June 2026

Longevity explained simply: healthspan, the "Hallmarks of Aging" and why research is being done

"Longevity" has become a buzzword, but there is more behind it than the promise of a long life. In science, the focus is less on accumulating as many years as possible and more on staying healthy and functional for as long as possible - the so-called healthspan. This article explains, in a beginner-friendly way, what drives aging biologically, what the much-cited "Hallmarks of Aging" are, and why researchers are studying compounds and peptides that might intervene in these processes. Important up front: much of this is basic research, often in cells or animals, and far from being translated into robust human evidence. We sort out what is established, what is hope, and where the gaps lie.

Machine-assisted translation. The German original is the authoritative version.

Key points

In science, longevity refers above all to a longer healthspan, not just more years of life.
The "Hallmarks of Aging" (9 in the 2013 version, 12 in the 2023 one) are an organizing model of interconnected aging processes - aging has no single cause.
Compounds and peptides are being researched to influence individual hallmarks; however, the data are mostly preclinical (cell/animal).
Robust human evidence for an extended healthspan is lacking for most longevity peptides; much of what comes from the community is claim, not fact.
The regulatory status is often critical (investigational substance, not approved) - for concrete questions, the decision belongs in medical hands.

Lifespan is not the same as healthspan

When longevity comes up, many people first think of lifespan - that is, the sheer number of years lived. In aging research, however, a different concept takes center stage: healthspan, the period during which a person lives free of serious chronic diseases and functional limitations. The goal of serious research is not to postpone dying endlessly, but to shorten the years of illness and frailty at the end of life.

The background is the observation that age itself is the greatest risk factor for most chronic diseases - from cardiovascular disease to cancer to dementia. The research field of geroscience starts from the assumption that these diseases share common biological roots in the aging process. Tackling these roots could, in theory, delay several age-related ailments at once, instead of treating each disease individually. This idea is plausible and scientifically well grounded, but so far it is primarily a research strategy - not a proven treatment path for humans.

Lifespan = number of years lived; healthspan = years without serious disease/limitation
Age is the most important risk factor for most chronic diseases
Geroscience approach: address common biological causes of aging instead of just individual diseases

The "Hallmarks of Aging" - a framework for understanding aging

An influential review article in the journal Cell summarized aging in 2013 into nine "Hallmarks of Aging" - recurring cellular and molecular processes that can be observed across different organisms. An expanded version from 2023 names twelve such hallmarks. This framework is not a law of nature but a useful organizing model that guides a large part of today's research.

The hallmarks include, among others, genomic instability (damage to the genetic material), telomere shortening (the wearing down of the protective caps on chromosomes), epigenetic alterations, loss of protein quality control, deregulated nutrient sensing by the cell, mitochondrial dysfunction (problems with the cell's "power plants"), cellular senescence (aging cells that can no longer divide), stem cell exhaustion, and altered communication between cells. The expanded list adds, among others, chronic inflammation and a disrupted microbiome. What is decisive: these hallmarks are closely interwoven and influence one another - there is no single "switch" that could simply be flipped.

2013: nine hallmarks; 2023: expanded to twelve hallmarks
Examples: telomere shortening, cellular senescence, mitochondrial dysfunction, chronic inflammation
The hallmarks are interconnected - aging has no single cause
The model organizes research but is not a complete explanatory system

Why compounds and peptides are being researched

From the hallmarks comes the research logic behind many of the compounds being studied: if a single hallmark of aging can be selectively influenced, this might slow the overall process. Researchers are therefore studying, for example, substances meant to modulate the cell's nutrient sensing, to remove senescent cells (so-called senolytics), or to support mitochondrial function.

Peptides - short chains of amino acids - are interesting in this context because many of the body's own signaling molecules are themselves peptides and could act on specific control points. Mitochondrially encoded peptides such as MOTS-c or Humanin, for instance, are being studied in basic research in connection with metabolism and cellular stress; synthetic compounds such as the mitochondria-targeting SS-31 (Elamipretide) or the pineal peptide Epitalon are the subject of studies. Important for context: the bulk of this data comes from cell and animal experiments. Robust, controlled human studies with endpoints such as extended healthspan are largely lacking for most of these peptides. What is often portrayed in the community as an established "anti-aging" benefit is mostly a claim that is not (yet) scientifically well supported.

Research logic: influence individual hallmarks to slow the aging process
Peptides are interesting because many of the body's own signaling molecules are themselves peptides
Examples from basic research: MOTS-c, Humanin, SS-31 (Elamipretide), Epitalon
Data are mostly preclinical (cell/animal); robust human evidence is usually lacking

An honest look at evidence and regulatory status

On hardly any topic do promises and the state of the evidence diverge as widely as with longevity compounds. A well-documented example of a serious approach is the planned TAME study (Targeting Aging with Metformin): it aims to test whether metformin, the diabetes drug that has been approved for decades, can delay the onset of several age-related diseases. What is remarkable is less the expected effect than the regulatory goal - getting "aging" recognized as a treatable condition for studies in the first place. This shows: even for an established substance, proof in humans is still pending.

For many of the peptides traded within the longevity scene, the regulatory status must be assessed far more critically. They are generally not approved as medicines for "life extension"; some are purely investigational or research substances, others are at best prescribed for narrowly defined medical indications or are not regulated at all. Obtaining them outside of medical supervision is associated with considerable risks - such as unknown purity, lack of quality assurance, and unclear long-term safety. This article deliberately names no sources, amounts, or usage schemes, because there is no reliable basis for them and such decisions belong in medical hands.

Promises and the state of evidence diverge widely for longevity compounds
The TAME study (metformin) is planned - even here proof in humans is still pending
Many peptides: not approved for "life extension", some purely investigational substances
Obtaining them without medical supervision carries risks: purity, quality, long-term safety unclear

Putting the hype in perspective - staying level-headed

Longevity is a fascinating, fast-growing field of research that is likely to deliver important insights in the coming years. At the same time, it is a market where a great deal of money is moved with big promises. Anyone wanting to find their bearings should distinguish between three levels: well-supported fundamentals (for example, that aging has common biological mechanisms), plausible but unproven hypotheses (that these mechanisms can be safely and effectively influenced in humans), and pure claims from marketing and communities.

A healthy lifestyle - exercise, sleep, nutrition, social connection - remains the thing for which the most robust evidence for a longer healthspan exists; this is unspectacular but well documented. New compounds and peptides are a legitimate field of research, but not a guaranteed shortcut. For concrete health questions or considerations about substances, medical advice is the right place to turn - not a forum or a vendor.

Separate three levels: supported fundamentals, plausible hypotheses, pure claims
Lifestyle (exercise, sleep, nutrition, social connection) has the most robust evidence
New compounds are research, not a guaranteed shortcut
For concrete questions: seek medical advice, do not trust forums or vendors

Related substance profiles

MOTS-c

A mitochondrially encoded peptide — an "exercise mimetic" of research, not approved.

SS-31 (Elamipretid)

A cardiolipin-stabilizing mitochondrial peptide — approved in the USA for Barth syndrome in 2025.

Epitalon (Epithalon)

Synthetic tetrapeptide — research substance for aging, not approved.

Humanin

Mitochondria-derived 24-amino-acid peptide from neuro- and longevity research — experimental, not approved.

Frequently asked questions

Is "longevity" the same as a longer life?: Not quite. In research, the focus is less on lifespan alone than on healthspan - that is, the years one spends without serious chronic disease and functional limitation. The goal is to age in good health, not to postpone dying endlessly.
Can peptides stop aging?: There is currently no robust proof of this in humans. Some peptides are being studied in basic research because they might act on mechanisms of aging, but most of the data come from cell and animal experiments. Statements that a peptide "stops aging" must be classified as an unsupported claim.
Are these compounds approved and safe?: The status varies greatly. Some of the substances studied are purely investigational or research substances, others are at best prescribed for narrowly defined medical indications - but not approved for "life extension". Purity, quality, and long-term safety are often unclear outside of medical supervision. For concrete considerations, medical advice is warranted.

Sources

This article is for information and education only. It does not replace medical advice and deliberately contains no dosing, usage or sourcing information.

← All guide articles